B. Riley lowered shares of Sensus Healthcare (NASDAQ:SRTS) from a buy rating to a neutral rating in a report issued on Thursday morning, Briefing.com Automated Import reports. B. Riley currently has $5.50 target price on the stock, down from their prior target price of $14.00.
SRTS has been the topic of several other research reports. HC Wainwright reiterated a buy rating and issued a $10.00 price objective on shares of Sensus Healthcare in a report on Thursday. TheStreet upgraded Sensus Healthcare from a d+ rating to a c- rating in a report on Monday, August 26th. Maxim Group set a $11.00 price objective on Sensus Healthcare and gave the stock a buy rating in a report on Friday, August 9th. Finally, ValuEngine downgraded Sensus Healthcare from a buy rating to a hold rating in a report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of Hold and a consensus price target of $8.30.
Shares of Sensus Healthcare stock traded down $0.21 during trading hours on Thursday, reaching $3.80. The company had a trading volume of 73,900 shares, compared to its average volume of 31,014. The business has a fifty day simple moving average of $5.73 and a 200 day simple moving average of $5.72. Sensus Healthcare has a one year low of $3.71 and a one year high of $9.23. The firm has a market cap of $93.54 million, a PE ratio of -27.14 and a beta of -0.41.
Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $5.84 million during the quarter, compared to analyst estimates of $7.77 million. Sensus Healthcare had a negative return on equity of 8.82% and a negative net margin of 8.65%. As a group, equities research analysts predict that Sensus Healthcare will post -0.12 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN purchased a new position in shares of Sensus Healthcare in the second quarter worth about $30,000. Susquehanna International Group LLP increased its holdings in shares of Sensus Healthcare by 69.9% in the second quarter. Susquehanna International Group LLP now owns 27,492 shares of the company’s stock worth $152,000 after buying an additional 11,311 shares during the period. Essex Investment Management Co. LLC purchased a new position in shares of Sensus Healthcare in the third quarter worth about $540,000. BlackRock Inc. increased its holdings in Sensus Healthcare by 40.7% during the 2nd quarter. BlackRock Inc. now owns 103,643 shares of the company’s stock valued at $574,000 after purchasing an additional 29,990 shares during the period. Finally, Heartland Advisors Inc. increased its holdings in Sensus Healthcare by 150.0% during the 2nd quarter. Heartland Advisors Inc. now owns 375,000 shares of the company’s stock valued at $2,078,000 after purchasing an additional 225,000 shares during the period. Hedge funds and other institutional investors own 9.95% of the company’s stock.
Sensus Healthcare Company Profile
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.